Neutropenia, Severe Congenital, Autosomal Recessive 3 clinical trials

The registry lists 22 studies for Neutropenia, Severe Congenital, Autosomal Recessive 3 across more than 10 countries. 7 are recruiting or about to start. 3 of them are mainly about Neutropenia, Severe Congenital, Autosomal Recessive 3 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Neutropenia, Severe Congenital, Autosomal Recessive 3 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Status

Completed: 10
Recruiting: 6
Terminated: 3
Active, not recruiting: 2
Not yet recruiting: 1

Phase

Phase 2: 10
Phase 1: 6
Phase 3: 2
Early Phase 1: 1

Where

United States: 18
Belgium: 2
Italy: 2
France: 2
Malaysia: 1
Georgia: 1

Who runs them

University of California, San Francisco (3) · Masonic Cancer Center, University of Minnesota (2) · Roswell Park Cancer Institute (2) · St. Jude Children's Research Hospital (2) · Emory University (2) · Diane George (2) · Centre Hospitalier Universitaire de Liege (1) · Centre Hospitalier Universitaire Dijon (1)

What is being tested here

Drugs under test in Neutropenia, Severe Congenital, Autosomal Recessive 3 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Mavorixafor	1	1	1
Fludarabine	0	1	7
Fludarabine phosphate	0	0	5
Busulfan	0	1	4
Melphalan	0	0	2
Alemtuzumab	0	1	2
Cyclophosphamide	0	1	2
Abatacept	0	0	1
Antilymphocyte Serum	0	0	1
Therapeutic Allogeneic Lymphocytes	0	0	1

Drug classes tested here Alkylating agents 7 · Antimetabolites 7

Coming up

1phase 3 study under way

3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Sep 2027A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections · Phase 3 · X4 Pharmaceuticals
Dec 2026AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion · Mitchell Cairo
Dec 2026Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data · Istituto Giannina Gaslini

Who these studies take

Of the 6 Neutropenia, Severe Congenital, Autosomal Recessive 3 studies recruiting now, 4 (67%) set no upper age limit and 2 (33%) stop at 75 or younger. 6 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 6
Age	Women	Men
10	5 (83%)	5 (83%)
18	6 (100%)	6 (100%)
30	6 (100%)	6 (100%)
40	5 (83%)	5 (83%)
50	5 (83%)	5 (83%)
65	5 (83%)	5 (83%)
75	4 (67%)	4 (67%)
85	4 (67%)	4 (67%)

Across all 22 studies, recruiting or not: 77% stop at 75 or younger and 68% at 65; 100% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 16, 2026.

Newly registered1

Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic DataOct 16, 2026NCT07877727

Studies

Recruiting first, then most recently updated. Showing 22 of 22. search them.